EHMT2 and acute lymphoblastic leukemia: In this manuscript, the intersection of multiple “omics” approaches identified G9a as a therapeutic target in T-cell acute lymphoblastic leukemia (T-ALL), an aggressive neoplastic disorder of lymphoblasts committed to the T-cell lineage in need of new treatment modalities, particularly in relapsed/refractory cases [13].